Moderate

Epilepsy in pregnancy and preconception planning

Women with epilepsy · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Management of women with epilepsy before and during pregnancy to balance seizure control against teratogenic and developmental risks of antiseizure medication. Requires preconception optimisation, high-dose folate and specialist joint care.

Red flags

  • New seizures after 20 weeks (exclude eclampsia/CVST)
  • Status epilepticus in pregnancy
  • Rising seizure frequency from falling drug levels
  • Unplanned pregnancy on valproate
  • Postpartum medication toxicity from un-reduced dose

Assessment

Differential diagnosis

  • Eclampsia (new seizures in late pregnancy)
  • Gestational exacerbation of known epilepsy
  • Psychogenic non-epileptic seizures
  • Cerebral venous sinus thrombosis
  • Posterior reversible encephalopathy syndrome
  • Hyponatraemia or metabolic seizures

Investigations

  • Confirm epilepsy diagnosis and seizure type before pregnancy
  • Baseline and serial lamotrigine or levetiracetam levels (clearance rises in pregnancy)
  • Antiseizure medication review for teratogenic potential
  • Detailed fetal anomaly ultrasound at 18-20 weeks
  • Vitamin D and medication adherence assessment
  • In new late-pregnancy seizures: BP, urinalysis, bloods and imaging to exclude eclampsia/CVST

Management

  • Discuss contraception and planned pregnancy with every woman of childbearing potential on antiseizure medication
  • Avoid sodium valproate in women who may become pregnant unless no alternative and under a pregnancy prevention programme
  • Switch to lower-risk agent (lamotrigine or levetiracetam) before conception, not after
  • Start folic acid 5 mg daily before conception and continue through first trimester
  • Aim for monotherapy at the lowest effective dose
  • Monitor lamotrigine/levetiracetam levels through pregnancy and increase dose as clearance rises
  • Reduce dose back toward pre-pregnancy levels in early postpartum to avoid toxicity
  • Arrange joint obstetric-neurology antenatal care and enrol in a pregnancy register
  • Plan delivery with seizure precautions and continued medication
  • Counsel on safe infant care (changing on floor, supervised bathing) and support breastfeeding on most agents

Drugs & doses

Folic acid 5 mg PO daily preconception and first trimester
Lamotrigine (monotherapy, dose adjusted to serum levels through pregnancy)
Levetiracetam (monotherapy, dose increased as clearance rises)
Avoid sodium valproate (high teratogenic and neurodevelopmental risk)
Vitamin K 1 mg IM to neonate at birth per local policy

Disposition

Joint neurology-obstetric specialist antenatal clinic. Enrol in epilepsy pregnancy register. Urgent assessment for new seizures in pregnancy.

Complications & pitfalls

  • Major congenital malformation and neurodevelopmental harm (especially valproate)
  • Breakthrough seizures from pregnancy pharmacokinetics
  • Postpartum toxicity if dose not reduced
  • Seizure-related maternal and fetal injury
  • SUDEP risk with poor control

Exam pearls

  • Optimise medication before conception, never discover epilepsy risk at the booking visit
  • Lamotrigine clearance can double by late pregnancy; monitor levels and pre-empt dose rises
  • Reduce lamotrigine promptly postpartum to avoid toxicity
  • Most antiseizure medications are compatible with breastfeeding

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.